Elutia Earnings Call Transcripts
Fiscal Year 2026
-
A new drug-eluting biologic for breast reconstruction aims to address a $1.5B market with high infection rates by delivering antibiotics directly at the surgical site. FDA approval for the base matrix is expected this year, with the drug-eluting version targeted for next year.
Fiscal Year 2025
-
Revenue grew 16% year-over-year to $3.3M with improved gross margins and reduced net loss. Strategic sale of BioEnvelope enabled debt repayment and a strong cash position, supporting the focus on NXT-41x for the large breast reconstruction market.
-
Q3 2025 saw the $88M sale of the BioEnvelope business, strengthening the balance sheet and validating the technology. SimpliDerm and Cardiovascular segments showed sequential growth, with improved gross margins and reduced operating expenses. Sufficient cash runway supports NXT-41/41x development and commercialization.
-
A proven drug-eluting biologics platform is being expanded from pacemaker applications to address high infection rates in breast reconstruction, targeting a $1.5 billion market with significant unmet need. The company is fully funded, with FDA filings for its next product expected in 2026.
-
Management highlighted strong commercial traction for EluPro, a drug-eluting biologic for pacemakers, and plans to scale hospital adoption with Boston Scientific and GPO support. The pipeline includes NXT-41X for breast reconstruction, with approval expected in 2027. The company seeks non-dilutive capital and margin improvement.
-
EluPro drove 49% sequential growth and now dominates BioEnvelope revenue, with strong hospital adoption and improved gross margins. NXT-41x breast reconstruction platform is on track for 2026–2027 launches, and legacy litigation is nearly resolved, reducing risk.
-
EluPro's launch drove strong BioEnvelope growth, aided by a major Boston Scientific partnership and expanded manufacturing. Sequential revenue gains, improved margins, and new financing strengthen the outlook, with direct cardiovascular sales and clinical data expected to further boost performance.
-
EluPro, a drug-eluting biologic envelope for pacemakers, is gaining rapid traction with strong clinical and commercial advantages, supported by a major partnership with Boston Scientific. The company is expanding its pipeline and production capacity, aiming for significant growth in 2026.
Fiscal Year 2024
-
EluPro's pilot launch drove 18% Q4 growth in device protection sales, with rapid adoption and strong physician support. SimpliDerm grew 12% for the year despite Q4 disruption, and a new Boston Scientific partnership is set to accelerate EluPro's expansion.
-
Q3 2024 saw the first commercial use of EluPro, now 25% of bioenvelope sales, and 19% growth in SimpliDerm. Revenue was $5.9M, with a 61% adjusted gross margin and $25.7M in cash. Full EluPro launch is set for January 2025.
-
EluPro, a new drug-eluting biologic for pacemakers, is launching in January with strong clinical and market advantages, targeting a $600 million market and supported by robust hospital and distributor relationships. SimpliDerm, for breast reconstruction, is also growing rapidly and will soon incorporate drug-eluting technology.
-
EluPro, a first-in-class antibiotic-eluting bioenvelope, is launching into a $600 million US market for pacemaker and defibrillator protection, targeting a large unmet need left by Medtronic’s TYRX. With strong physician interest and a robust financial position, full launch is set for January 2025.
-
Regulatory approval and initial production of EluPro mark a pivotal quarter, with strong physician interest and expanded market opportunities. Financials show stable sales, improved margins, and a strengthened cash position exceeding $30M after recent financings.